IRBM to receive EIB funding to expand R&D into COVID-19
IRBM’s goal will be to help ensure a more resilient global response to future epidemics by producing second generation vaccines and treatments for SARS-CoV-2 and new coronaviruses.
List view / Grid view
IRBM’s goal will be to help ensure a more resilient global response to future epidemics by producing second generation vaccines and treatments for SARS-CoV-2 and new coronaviruses.
The facility is designed around a central unit that comprises several fully digitalised modules, which can produce up to four vaccines simultaneously, regardless of the vaccine technology used.
The results of a recent international study suggest that left-handed gold nanoparticles can increase vaccine effectiveness by 25 percent, providing useful adjuvant capabilities.
Water content determination of Ibuprofen tablets with an automated Karl Fischer titrator coupling with gas phase extraction.
A lot of Moderna’s Spikevax® vaccine is being recalled due to particulates, just six months after previous contamination concerns were supposedly solved.
The closing of two biologics acquisitions will help Recipharm establish itself in the advanced therapy medicinal products space.
The examples of common applications in the pharmaceutical industry for titration, UV/VIS spectroscopy and physical values are presented in details.
7 April 2022 | By Charles River
Watch experts discuss key aspects of microbial investigations, helping you to understand and implement the new PDA Technical Report 88, and sharing their experience of investigating various microbial events in the real world.
Catalent announces the expansion of its biologics development and manufacturing capability by purchasing a new facility, currently under construction in Oxford, UK.
A team of scientists has developed a spherical nucleic acid (SNA) vaccine, which has demonstrated high efficacy as a COVID-19 therapy, as well as an anti-cancer treatment in rodents.
Ami Polymer are experts in manufacture of silicone tubing, hose and single use assembly with PPE components, which is demanded in pharma/biopharma industry.
The March meeting saw the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommend five medications for approval including a multiple myeloma gene therapy.
The new mRNA vaccine programmes are aimed at the major causative agents of respiratory tract infections, respiratory syncytial virus (RSV), influenza and coronaviruses.
A new paper details the GMP manufacturing and formulation process for a semi-synthetic Shigella glycoconjugate vaccine candidate from Institut Pasteur.
Will mRNA vaccines one day protect against HIV? Three investigational mRNA vaccines, all designed to combat HIV, have entered Phase I testing.